Zhittya Logo.jpg
Mr. Daniel C. Montano, CEO, is recognized as Biotech Entrepreneur of the Year and Dr. Marc Kahn as Medical Professional of the Year by the Nevada Biotechnology & Health Science Consortium
June 17, 2021 13:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, June 17, 2021 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), is proud to announce that Mr. Daniel C. Montano, CEO, and founder of...
Picture1.png
The Nevada Biotechnology & Health Science Consortium is Recognizing Dr. Marc Kahn as Medical Professional of the Year and Daniel C. Montano as the Biotech Entrepreneur of the Year
June 15, 2021 11:00 ET | Nevada Biotechnology & Health Science Consortium
LAS VEGAS, June 15, 2021 (GLOBE NEWSWIRE) -- The Nevada Biotechnology & Health Science Consortium (NevBio) was founded in 2007 to encourage the development and expansion of the Health Sciences...
Surrozen Logo FINAL Large-1.png
Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference
May 24, 2021 08:00 ET | Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Histogen logo 300.jpg
Histogen and Amerimmune Report Publication on Emricasan in COVID-19
May 19, 2021 08:00 ET | Histogen Inc
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen Reports First Quarter 2021 Earnings and Provides Business Update
May 13, 2021 16:01 ET | Histogen Inc
Strengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises Initiated Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients with Top-Line Data...
Surrozen Logo FINAL Large-1.png
Surrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai
May 06, 2021 08:00 ET | Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Bone Bank Allografts Announces Partnership Capstone Health Alliance
April 27, 2021 16:30 ET | Bone Bank Allografts (BBA)
SAN ANTONIO, April 27, 2021 (GLOBE NEWSWIRE) -- Bone Bank Allografts (BBA), a leading provider of regenerative medicine technologies to the surgical community, announced a multi-year supplier...
AMR Logo.png
South Korea Cell Culture Market to Garner $606.4 Million by 2027: Allied Market Research
April 27, 2021 10:20 ET | Allied Market Research
Portland, OR , April 27, 2021 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the South Korea cell culture market was accounted for $216.3 million in 2019, and is...
lsif-logo-default (1).png
Sernova to Webcast Live at Life Sciences Investor Forum March 25th
March 22, 2021 10:36 ET | Life Sciences Investor Forum
LONDON, Ontario, March 22, 2021 (GLOBE NEWSWIRE) -- Sernova Corp. (OTCQB:SEOVF)(TSX-V:SVA)(FSE/XETRA:PSH), a leading clinical-stage company focused on developing regenerative medicine therapeutics...
Histogen logo 300.jpg
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
February 16, 2021 08:00 ET | Histogen Inc
HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:...